271 related articles for article (PubMed ID: 33863281)
1. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19.
Jin C; Yu B; Zhang J; Wu H; Zhou X; Yao H; Liu F; Lu X; Cheng L; Jiang M; Wu N
BMC Infect Dis; 2021 Apr; 21(1):357. PubMed ID: 33863281
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of SARS-CoV-2 infectivity in platelet concentrates or plasma following treatment with ultraviolet C light or with methylene blue combined with visible light.
Hobson-Peters J; Amarilla AA; Rustanti L; Marks DC; Roulis E; Khromykh AA; Modhiran N; Watterson D; Reichenberg S; Tolksdorf F; Sumian C; Seltsam A; Gravemann U; Faddy HM
Transfusion; 2023 Feb; 63(2):288-293. PubMed ID: 36573801
[TBL] [Abstract][Full Text] [Related]
3. Antiviral photodynamic therapy: Inactivation and inhibition of SARS-CoV-2 in vitro using methylene blue and Radachlorin.
Svyatchenko VA; Nikonov SD; Mayorov AP; Gelfond ML; Loktev VB
Photodiagnosis Photodyn Ther; 2021 Mar; 33():102112. PubMed ID: 33249118
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light.
Eickmann M; Gravemann U; Handke W; Tolksdorf F; Reichenberg S; Müller TH; Seltsam A
Vox Sang; 2020 Apr; 115(3):146-151. PubMed ID: 31930543
[TBL] [Abstract][Full Text] [Related]
5. Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro.
Cagno V; Medaglia C; Cerny A; Cerny T; Zwygart AC; Cerny E; Tapparel C
Sci Rep; 2021 Jul; 11(1):14295. PubMed ID: 34253743
[TBL] [Abstract][Full Text] [Related]
6. Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light.
Larrea L; Castro E; Navarro L; Vera B; Francés-Gómez C; Sánchez-Sendra B; Giménez Á; Castelló E; Collado M; Vayá MJ; Mirabet V; Callao V; Ortiz-de-Salazar MI; Roig R; Geller R; Arbona C
Blood Transfus; 2022 May; 20(3):206-212. PubMed ID: 34369870
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment.
Keil SD; Ragan I; Yonemura S; Hartson L; Dart NK; Bowen R
Vox Sang; 2020 Aug; 115(6):495-501. PubMed ID: 32311760
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively.
Eickmann M; Gravemann U; Handke W; Tolksdorf F; Reichenberg S; Müller TH; Seltsam A
Transfusion; 2018 Sep; 58(9):2202-2207. PubMed ID: 29732571
[TBL] [Abstract][Full Text] [Related]
9. Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human plasma.
Azhar EI; Hindawi SI; El-Kafrawy SA; Hassan AM; Tolah AM; Alandijany TA; Bajrai LH; Damanhouri GA
Vox Sang; 2021 Jul; 116(6):673-681. PubMed ID: 33277935
[TBL] [Abstract][Full Text] [Related]
10. Exploring inactivation of SARS-CoV-2, MERS-CoV, Ebola, Lassa, and Nipah viruses on N95 and KN95 respirator material using photoactivated methylene blue to enable reuse.
Scholte FEM; Kabra KB; Tritsch SR; Montgomery JM; Spiropoulou CF; Mores CN; Harcourt BH
Am J Infect Control; 2022 Aug; 50(8):863-870. PubMed ID: 35908824
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings.
Widera M; Westhaus S; Rabenau HF; Hoehl S; Bojkova D; Cinatl J; Ciesek S
Med Microbiol Immunol; 2021 Aug; 210(4):235-244. PubMed ID: 34196781
[TBL] [Abstract][Full Text] [Related]
12. Pathogen reduction with methylene blue does not have an impact on the clinical effectiveness of COVID-19 convalescent plasma.
Romera Martínez I; Bueno Cabrera JL; Domingo-Morera JM; López Aguilar JC; Villegas Da Ros C; García Erce JA; Sáez Serrano I; Flores Ballester E; Maglio LA; Arbona Castaño C; Sola Lapeña C; Guerra Domínguez L; Berberana Fernández M; Madrigal Sánchez ME; Rubio Batllés M; Pérez-Olmeda M; Ramos-Martínez A; Velasco-Iglesias A; Avendaño-Solá C; Duarte RF
Vox Sang; 2023 Apr; 118(4):296-300. PubMed ID: 36734378
[TBL] [Abstract][Full Text] [Related]
13. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial.
Alemany A; Millat-Martinez P; Corbacho-Monné M; Malchair P; Ouchi D; Ruiz-Comellas A; Ramírez-Morros A; Rodríguez Codina J; Amado Simon R; Videla S; Costes G; Capdevila-Jáuregui M; Torrano-Soler P; San José A; Bonet Papell G; Puig J; Otero A; Ruibal Suarez JC; Zarauza Pellejero A; Llopis Roca F; Rodriguez Cortez O; Garcia Garcia V; Vidal-Alaball J; Millan A; Contreras E; Grifols JR; Ancochea À; Galvan-Femenia I; Piccolo Ferreira F; Bonet M; Cantoni J; Prat N; Ara J; Forcada Arcarons A; Farré M; Pradenas E; Blanco J; Àngel Rodriguez-Arias M; Fernández Rivas G; Marks M; Bassat Q; Blanco I; Baro B; Clotet B; Mitjà O;
Lancet Respir Med; 2022 Mar; 10(3):278-288. PubMed ID: 35150610
[TBL] [Abstract][Full Text] [Related]
14. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
[TBL] [Abstract][Full Text] [Related]
15. Methylene blue inhibits replication of SARS-CoV-2 in vitro.
Gendrot M; Andreani J; Duflot I; Boxberger M; Le Bideau M; Mosnier J; Jardot P; Fonta I; Rolland C; Bogreau H; Hutter S; La Scola B; Pradines B
Int J Antimicrob Agents; 2020 Dec; 56(6):106202. PubMed ID: 33075512
[TBL] [Abstract][Full Text] [Related]
16. Validation of Viral Inactivation Protocols for Therapeutic Blood Products against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-COV-2).
Belem WF; Liu CH; Hu YT; Burnouf T; Lin LT
Viruses; 2022 Oct; 14(11):. PubMed ID: 36366517
[TBL] [Abstract][Full Text] [Related]
17. Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma.
Kostin AI; Lundgren MN; Bulanov AY; Ladygina EA; Chirkova KS; Gintsburg AL; Logunov DY; Dolzhikova IV; Shcheblyakov DV; Borovkova NV; Godkov MA; Bazhenov AI; Shustov VV; Bogdanova AS; Kamalova AR; Ganchin VV; Dombrovskiy EA; Volkov SE; Drozdova NE; Petrikov SS
Vox Sang; 2021 Jul; 116(6):665-672. PubMed ID: 33734455
[TBL] [Abstract][Full Text] [Related]
18. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light.
Ragan I; Hartson L; Pidcoke H; Bowen R; Goodrich R
PLoS One; 2020; 15(5):e0233947. PubMed ID: 32470046
[TBL] [Abstract][Full Text] [Related]
19. Two pathogen reduction technologies--methylene blue plus light and shortwave ultraviolet light--effectively inactivate hepatitis C virus in blood products.
Steinmann E; Gravemann U; Friesland M; Doerrbecker J; Müller TH; Pietschmann T; Seltsam A
Transfusion; 2013 May; 53(5):1010-8. PubMed ID: 22905868
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of Middle East respiratory syndrome-coronavirus in human plasma using amotosalen and ultraviolet A light.
Hindawi SI; Hashem AM; Damanhouri GA; El-Kafrawy SA; Tolah AM; Hassan AM; Azhar EI
Transfusion; 2018 Jan; 58(1):52-59. PubMed ID: 29239484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
